Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 937 to 947 of 947 entries
Sorted by: Best Match Show Resources per page
Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions.

Cell reports. Medicine

Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE, Baric RS, Morris L, McLellan JS, Georgiev IS.
PMID: 34056628
Cell Rep Med. 2021 Jun 15;2(6):100313. doi: 10.1016/j.xcrm.2021.100313. Epub 2021 May 21.

The continual emergence of novel coronaviruses (CoV), such as severe acute respiratory syndrome-(SARS)-CoV-2, highlights the critical need for broadly reactive therapeutics and vaccines against this family of viruses. From a recovered SARS-CoV donor sample, we identify and characterize a...

Cite
Shiakolas AR, Kramer KJ, Wrapp D, et al. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021;2(6):100313doi: 10.1016/j.xcrm.2021.100313.
Shiakolas, A. R., Kramer, K. J., Wrapp, D., Richardson, S. I., Schäfer, A., Wall, S., Wang, N., Janowska, K., Pilewski, K. A., Venkat, R., Parks, R., Manamela, N. P., Raju, N., Fechter, E. F., Holt, C. M., Suryadevara, N., Chen, R. E., Martinez, D. R., Nargi, R. S., Sutton, R. E., Ledgerwood, J. E., Graham, B. S., Diamond, M. S., Haynes, B. F., Acharya, P., Carnahan, R. H., Crowe, J. E., Baric, R. S., Morris, L., McLellan, J. S., & Georgiev, I. S. (2021). Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell reports. Medicine, 2(6), 100313. https://doi.org/10.1016/j.xcrm.2021.100313
Shiakolas, Andrea R, et al. "Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions." Cell reports. Medicine vol. 2,6 (2021): 100313. doi: https://doi.org/10.1016/j.xcrm.2021.100313
Shiakolas AR, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski KA, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE, Baric RS, Morris L, McLellan JS, Georgiev IS. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. Cell Rep Med. 2021 Jun 15;2(6):100313. doi: 10.1016/j.xcrm.2021.100313. Epub 2021 May 21. PMID: 34056628; PMCID: PMC8139315.
Copy Download .nbib Format: NLM
Impact of Comorbidities, Sarcopenia, and Nutritional Status on the Long-Term Outcomes after Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients Aged ≥ 80 Years.

Cancers

Kim GH, Choi KD, Ko Y, Park T, Kim KW, Park SY, Na HK, Ahn JY, Lee JH, Jung KW, Kim DH, Song HJ, Lee GH, Jung HY.
PMID: 34298811
Cancers (Basel). 2021 Jul 18;13(14). doi: 10.3390/cancers13143598.

BACKGROUND/AIM: We investigated the oncologic outcomes in elderly patients who underwent endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) by focusing on the impact of comorbidities, sarcopenia, and nutritional status.METHODS: Between 2005 and 2016, 280 patients aged ≥...

Cite
Kim GH, Choi KD, Ko Y, et al. Impact of Comorbidities, Sarcopenia, and Nutritional Status on the Long-Term Outcomes after Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients Aged ≥ 80 Years. Cancers (Basel). 2021;13(14)doi: 10.3390/cancers13143598.
Kim, G. H., Choi, K. D., Ko, Y., Park, T., Kim, K. W., Park, S. Y., Na, H. K., Ahn, J. Y., Lee, J. H., Jung, K. W., Kim, D. H., Song, H. J., Lee, G. H., & Jung, H. Y. (2021). Impact of Comorbidities, Sarcopenia, and Nutritional Status on the Long-Term Outcomes after Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients Aged ≥ 80 Years. Cancers, 13(14), . https://doi.org/10.3390/cancers13143598
Kim, Ga Hee, et al. "Impact of Comorbidities, Sarcopenia, and Nutritional Status on the Long-Term Outcomes after Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients Aged ≥ 80 Years." Cancers vol. 13,14 (2021). doi: https://doi.org/10.3390/cancers13143598
Kim GH, Choi KD, Ko Y, Park T, Kim KW, Park SY, Na HK, Ahn JY, Lee JH, Jung KW, Kim DH, Song HJ, Lee GH, Jung HY. Impact of Comorbidities, Sarcopenia, and Nutritional Status on the Long-Term Outcomes after Endoscopic Submucosal Dissection for Early Gastric Cancer in Elderly Patients Aged ≥ 80 Years. Cancers (Basel). 2021 Jul 18;13(14). doi: 10.3390/cancers13143598. PMID: 34298811; PMCID: PMC8304160.
Copy Download .nbib Format: NLM
The skin biopsy punch: a novel technique for half pin site incisions in circular frame application.

Annals of the Royal College of Surgeons of England

Walker MJ, Banks T, Thomas P.
PMID: 34719951
Ann R Coll Surg Engl. 2021 Nov;103(10):776-777. doi: 10.1308/rcsann.2021.0140.

No abstract available.

Cite
Walker MJ, Banks T, Thomas P. The skin biopsy punch: a novel technique for half pin site incisions in circular frame application. Ann R Coll Surg Engl. 2021;103(10):776-777doi: 10.1308/rcsann.2021.0140.
Walker, M. J., Banks, T., & Thomas, P. (2021). The skin biopsy punch: a novel technique for half pin site incisions in circular frame application. Annals of the Royal College of Surgeons of England, 103(10), 776-777. https://doi.org/10.1308/rcsann.2021.0140
Walker, M J, et al. "The skin biopsy punch: a novel technique for half pin site incisions in circular frame application." Annals of the Royal College of Surgeons of England vol. 103,10 (2021): 776-777. doi: https://doi.org/10.1308/rcsann.2021.0140
Walker MJ, Banks T, Thomas P. The skin biopsy punch: a novel technique for half pin site incisions in circular frame application. Ann R Coll Surg Engl. 2021 Nov;103(10):776-777. doi: 10.1308/rcsann.2021.0140. PMID: 34719951.
Copy Download .nbib Format: NLM
The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach.

BMC psychiatry

Correll CU, Chepke C, Gionfriddo P, Parks J, Foxworth P, Basu A, Brister TS, Brown D, Clarke C, Hassoun Y.
PMID: 35012512
BMC Psychiatry. 2022 Jan 10;22(1):32. doi: 10.1186/s12888-022-03685-w.

BACKGROUND: Long-acting injectable antipsychotics (LAIs) are an essential maintenance treatment option for individuals with schizophrenia or bipolar I disorder (BP-I). This report summarizes a roundtable discussion on the impact of COVID-19 on the mental healthcare landscape and use of...

Cite
Correll CU, Chepke C, Gionfriddo P, et al. The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. BMC Psychiatry. 2022;22(1):32doi: 10.1186/s12888-022-03685-w.
Correll, C. U., Chepke, C., Gionfriddo, P., Parks, J., Foxworth, P., Basu, A., Brister, T. S., Brown, D., Clarke, C., & Hassoun, Y. (2022). The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. BMC psychiatry, 22(1), 32. https://doi.org/10.1186/s12888-022-03685-w
Correll, Christoph U, et al. "The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach." BMC psychiatry vol. 22,1 (2022): 32. doi: https://doi.org/10.1186/s12888-022-03685-w
Correll CU, Chepke C, Gionfriddo P, Parks J, Foxworth P, Basu A, Brister TS, Brown D, Clarke C, Hassoun Y. The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. BMC Psychiatry. 2022 Jan 10;22(1):32. doi: 10.1186/s12888-022-03685-w. PMID: 35012512.
Copy Download .nbib Format: NLM
Developing a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein Model in a Viral Membrane.

bioRxiv : the preprint server for biology

Woo H, Park SJ, Choi YK, Park T, Tanveer M, Cao Y, Kern NR, Lee J, Yeom MS, Croll TI, Seok C, Im W.
PMID: 32511389
bioRxiv. 2020 Jun 17; doi: 10.1101/2020.05.20.103325.

This technical study describes all-atom modeling and simulation of a fully-glycosylated full-length SARS-CoV-2 spike (S) protein in a viral membrane. First, starting from PDB:6VSB and 6VXX, full-length S protein structures were modeled using template-based modeling, de-novo protein structure prediction,...

Cite
Woo H, Park SJ, Choi YK, et al. Developing a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein Model in a Viral Membrane. bioRxiv. 2020;doi: 10.1101/2020.05.20.103325.
Woo, H., Park, S. J., Choi, Y. K., Park, T., Tanveer, M., Cao, Y., Kern, N. R., Lee, J., Yeom, M. S., Croll, T. I., Seok, C., & Im, W. (2020). Developing a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein Model in a Viral Membrane. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2020.05.20.103325
Woo, Hyeonuk, et al. "Developing a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein Model in a Viral Membrane." bioRxiv : the preprint server for biology vol. (2020). doi: https://doi.org/10.1101/2020.05.20.103325
Woo H, Park SJ, Choi YK, Park T, Tanveer M, Cao Y, Kern NR, Lee J, Yeom MS, Croll TI, Seok C, Im W. Developing a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein Model in a Viral Membrane. bioRxiv. 2020 Jun 17; doi: 10.1101/2020.05.20.103325. PMID: 32511389; PMCID: PMC7263518.
Copy Download .nbib Format: NLM
Forecasting of the COVID-19 pandemic situation of Korea.

Genomics & informatics

Goo T, Apio C, Heo G, Lee D, Lee JH, Lim J, Han K, Park T.
PMID: 33840175
Genomics Inform. 2021 Mar;19(1):e11. doi: 10.5808/gi.21028. Epub 2021 Mar 25.

For the novel coronavirus disease 2019 (COVID-19), predictive modeling, in the literature, uses broadly susceptible exposed infected recoverd (SEIR)/SIR, agent-based, curve-fitting models. Governments and legislative bodies rely on insights from prediction models to suggest new policies and to assess...

Cite
Goo T, Apio C, Heo G, et al. Forecasting of the COVID-19 pandemic situation of Korea. Genomics Inform. 2021;19(1):e11doi: 10.5808/gi.21028.
Goo, T., Apio, C., Heo, G., Lee, D., Lee, J. H., Lim, J., Han, K., & Park, T. (2021). Forecasting of the COVID-19 pandemic situation of Korea. Genomics & informatics, 19(1), e11. https://doi.org/10.5808/gi.21028
Goo, Taewan, et al. "Forecasting of the COVID-19 pandemic situation of Korea." Genomics & informatics vol. 19,1 (2021): e11. doi: https://doi.org/10.5808/gi.21028
Goo T, Apio C, Heo G, Lee D, Lee JH, Lim J, Han K, Park T. Forecasting of the COVID-19 pandemic situation of Korea. Genomics Inform. 2021 Mar;19(1):e11. doi: 10.5808/gi.21028. Epub 2021 Mar 25. PMID: 33840175; PMCID: PMC8042305.
Copy Download .nbib Format: NLM
Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter study.

Journal of hepato-biliary-pancreatic sciences

Kim HS, Song W, Choo W, Lee S, Han Y, Bassi C, Salvia R, Marchegiani G, Wolfgang CL, He J, Blair AB, Kluger MD, Su GH, Kim SC, Song KB, Yamamoto M, Hatori T, Yang CY, Yamaue H, Hirono S, Satoi S, Fujii T, Hirano S, Lou W, Hashimoto Y, Shimizu Y, Del Chiaro M, Valente R, Lohr M, Choi DW, Choi SH, Heo JS, Motoi F, Matsumoto I, Lee WJ, Kang CM, Shyr YM, Wang SE, Han HS, Yoon YS, Besselink MG, van Huijgevoort NCM, Sho M, Nagano H, Kim SG, Honda G, Yang Y, Yu HC, Yang JD, Chung JC, Nagakawa Y, Seo HI, Lee S, Kim H, Kwon W, Park T, Jang JY.
PMID: 33811460
J Hepatobiliary Pancreat Sci. 2021 Apr 02; doi: 10.1002/jhbp.962. Epub 2021 Apr 02.

BACKGROUND: Although we previously proposed a nomogram to predict malignancy in intraductal papillary mucinous neoplasms (IPMN) and validated it in an external cohort, its application is challenging without data on tumor markers. Moreover, existing nomograms have not been compared....

Cite
Kim HS, Song W, Choo W, et al. Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter study. J Hepatobiliary Pancreat Sci. 2021;doi: 10.1002/jhbp.962.
Kim, H. S., Song, W., Choo, W., Lee, S., Han, Y., Bassi, C., Salvia, R., Marchegiani, G., Wolfgang, C. L., He, J., Blair, A. B., Kluger, M. D., Su, G. H., Kim, S. C., Song, K. B., Yamamoto, M., Hatori, T., Yang, C. Y., Yamaue, H., Hirono, S., Satoi, S., Fujii, T., Hirano, S., Lou, W., Hashimoto, Y., Shimizu, Y., Del Chiaro, M., Valente, R., Lohr, M., Choi, D. W., Choi, S. H., Heo, J. S., Motoi, F., Matsumoto, I., Lee, W. J., Kang, C. M., Shyr, Y. M., Wang, S. E., Han, H. S., Yoon, Y. S., Besselink, M. G., van Huijgevoort, N. C. M., Sho, M., Nagano, H., Kim, S. G., Honda, G., Yang, Y., Yu, H. C., Yang, J. D., Chung, J. C., Nagakawa, Y., Seo, H. I., Lee, S., Kim, H., Kwon, W., Park, T., & Jang, J. Y. (2021). Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter study. Journal of hepato-biliary-pancreatic sciences, . https://doi.org/10.1002/jhbp.962
Kim, Hyeong Seok, et al. "Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter study." Journal of hepato-biliary-pancreatic sciences vol. (2021). doi: https://doi.org/10.1002/jhbp.962
Kim HS, Song W, Choo W, Lee S, Han Y, Bassi C, Salvia R, Marchegiani G, Wolfgang CL, He J, Blair AB, Kluger MD, Su GH, Kim SC, Song KB, Yamamoto M, Hatori T, Yang CY, Yamaue H, Hirono S, Satoi S, Fujii T, Hirano S, Lou W, Hashimoto Y, Shimizu Y, Del Chiaro M, Valente R, Lohr M, Choi DW, Choi SH, Heo JS, Motoi F, Matsumoto I, Lee WJ, Kang CM, Shyr YM, Wang SE, Han HS, Yoon YS, Besselink MG, van Huijgevoort NCM, Sho M, Nagano H, Kim SG, Honda G, Yang Y, Yu HC, Yang JD, Chung JC, Nagakawa Y, Seo HI, Lee S, Kim H, Kwon W, Park T, Jang JY. Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter study. J Hepatobiliary Pancreat Sci. 2021 Apr 02; doi: 10.1002/jhbp.962. Epub 2021 Apr 02. PMID: 33811460.
Copy Download .nbib Format: NLM
Immunotherapy Treatment for Triple Negative Breast Cancer.

Pharmaceuticals (Basel, Switzerland)

Berger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N.
PMID: 34451860
Pharmaceuticals (Basel). 2021 Aug 04;14(8). doi: 10.3390/ph14080763.

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the early breast cancer setting can be upwards to 72% in 5 years, and...

Cite
Berger ER, Park T, Saridakis A, et al. Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals (Basel). 2021;14(8)doi: 10.3390/ph14080763.
Berger, E. R., Park, T., Saridakis, A., Golshan, M., Greenup, R. A., & Ahuja, N. (2021). Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals (Basel, Switzerland), 14(8), . https://doi.org/10.3390/ph14080763
Berger, Elizabeth R, et al. "Immunotherapy Treatment for Triple Negative Breast Cancer." Pharmaceuticals (Basel, Switzerland) vol. 14,8 (2021). doi: https://doi.org/10.3390/ph14080763
Berger ER, Park T, Saridakis A, Golshan M, Greenup RA, Ahuja N. Immunotherapy Treatment for Triple Negative Breast Cancer. Pharmaceuticals (Basel). 2021 Aug 04;14(8). doi: 10.3390/ph14080763. PMID: 34451860; PMCID: PMC8401402.
Copy Download .nbib Format: NLM
Prediction of protein assemblies, the next frontier: The CASP14-CAPRI experiment.

Proteins

Lensink MF, Brysbaert G, Mauri T, Nadzirin N, Velankar S, Chaleil RAG, Clarence T, Bates PA, Kong R, Liu B, Yang G, Liu M, Shi H, Lu X, Chang S, Roy RS, Quadir F, Liu J, Cheng J, Antoniak A, Czaplewski C, Giełdoń A, Kogut M, Lipska AG, Liwo A, Lubecka EA, Maszota-Zieleniak M, Sieradzan AK, Ślusarz R, Wesołowski PA, Zięba K, Del Carpio Muñoz CA, Ichiishi E, Harmalkar A, Gray JJ, Bonvin AMJJ, Ambrosetti F, Vargas Honorato R, Jandova Z, Jiménez-García B, Koukos PI, Van Keulen S, Van Noort CW, Réau M, Roel-Touris J, Kotelnikov S, Padhorny D, Porter KA, Alekseenko A, Ignatov M, Desta I, Ashizawa R, Sun Z, Ghani U, Hashemi N, Vajda S, Kozakov D, Rosell M, Rodríguez-Lumbreras LA, Fernandez-Recio J, Karczynska A, Grudinin S, Yan Y, Li H, Lin P, Huang SY, Christoffer C, Terashi G, Verburgt J, Sarkar D, Aderinwale T, Wang X, Kihara D, Nakamura T, Hanazono Y, Gowthaman R, Guest JD, Yin R, Taherzadeh G, Pierce BG, Barradas-Bautista D, Cao Z, Cavallo L, Oliva R, Sun Y, Zhu S, Shen Y, Park T, Woo H, Yang J, Kwon S, Won J, Seok C, Kiyota Y, Kobayashi S, Harada Y, Takeda-Shitaka M, Kundrotas PJ, Singh A, Vakser IA, Dapkūnas J, Olechnovič K, Venclovas Č, Duan R, Qiu L, Xu X, Zhang S, Zou X, Wodak SJ.
PMID: 34453465
Proteins. 2021 Dec;89(12):1800-1823. doi: 10.1002/prot.26222. Epub 2021 Sep 13.

We present the results for CAPRI Round 50, the fourth joint CASP-CAPRI protein assembly prediction challenge. The Round comprised a total of twelve targets, including six dimers, three trimers, and three higher-order oligomers. Four of these were easy targets,...

Cite
Lensink MF, Brysbaert G, Mauri T, et al. Prediction of protein assemblies, the next frontier: The CASP14-CAPRI experiment. Proteins. 2021;89(12):1800-1823doi: 10.1002/prot.26222.
Lensink, M. F., Brysbaert, G., Mauri, T., Nadzirin, N., Velankar, S., Chaleil, R. A. G., Clarence, T., Bates, P. A., Kong, R., Liu, B., Yang, G., Liu, M., Shi, H., Lu, X., Chang, S., Roy, R. S., Quadir, F., Liu, J., Cheng, J., Antoniak, A., Czaplewski, C., Giełdoń, A., Kogut, M., Lipska, A. G., Liwo, A., Lubecka, E. A., Maszota-Zieleniak, M., Sieradzan, A. K., Ślusarz, R., Wesołowski, P. A., Zięba, K., Del Carpio Muñoz, C. A., Ichiishi, E., Harmalkar, A., Gray, J. J., Bonvin, A. M. J. J., Ambrosetti, F., Vargas Honorato, R., Jandova, Z., Jiménez-García, B., Koukos, P. I., Van Keulen, S., Van Noort, C. W., Réau, M., Roel-Touris, J., Kotelnikov, S., Padhorny, D., Porter, K. A., Alekseenko, A., Ignatov, M., Desta, I., Ashizawa, R., Sun, Z., Ghani, U., Hashemi, N., Vajda, S., Kozakov, D., Rosell, M., Rodríguez-Lumbreras, L. A., Fernandez-Recio, J., Karczynska, A., Grudinin, S., Yan, Y., Li, H., Lin, P., Huang, S. Y., Christoffer, C., Terashi, G., Verburgt, J., Sarkar, D., Aderinwale, T., Wang, X., Kihara, D., Nakamura, T., Hanazono, Y., Gowthaman, R., Guest, J. D., Yin, R., Taherzadeh, G., Pierce, B. G., Barradas-Bautista, D., Cao, Z., Cavallo, L., Oliva, R., Sun, Y., Zhu, S., Shen, Y., Park, T., Woo, H., Yang, J., Kwon, S., Won, J., Seok, C., Kiyota, Y., Kobayashi, S., Harada, Y., Takeda-Shitaka, M., Kundrotas, P. J., Singh, A., Vakser, I. A., Dapkūnas, J., Olechnovič, K., Venclovas, �. �., Duan, R., Qiu, L., Xu, X., Zhang, S., Zou, X., & Wodak, S. J. (2021). Prediction of protein assemblies, the next frontier: The CASP14-CAPRI experiment. Proteins, 89(12), 1800-1823. https://doi.org/10.1002/prot.26222
Lensink, Marc F, et al. "Prediction of protein assemblies, the next frontier: The CASP14-CAPRI experiment." Proteins vol. 89,12 (2021): 1800-1823. doi: https://doi.org/10.1002/prot.26222
Lensink MF, Brysbaert G, Mauri T, Nadzirin N, Velankar S, Chaleil RAG, Clarence T, Bates PA, Kong R, Liu B, Yang G, Liu M, Shi H, Lu X, Chang S, Roy RS, Quadir F, Liu J, Cheng J, Antoniak A, Czaplewski C, Giełdoń A, Kogut M, Lipska AG, Liwo A, Lubecka EA, Maszota-Zieleniak M, Sieradzan AK, Ślusarz R, Wesołowski PA, Zięba K, Del Carpio Muñoz CA, Ichiishi E, Harmalkar A, Gray JJ, Bonvin AMJJ, Ambrosetti F, Vargas Honorato R, Jandova Z, Jiménez-García B, Koukos PI, Van Keulen S, Van Noort CW, Réau M, Roel-Touris J, Kotelnikov S, Padhorny D, Porter KA, Alekseenko A, Ignatov M, Desta I, Ashizawa R, Sun Z, Ghani U, Hashemi N, Vajda S, Kozakov D, Rosell M, Rodríguez-Lumbreras LA, Fernandez-Recio J, Karczynska A, Grudinin S, Yan Y, Li H, Lin P, Huang SY, Christoffer C, Terashi G, Verburgt J, Sarkar D, Aderinwale T, Wang X, Kihara D, Nakamura T, Hanazono Y, Gowthaman R, Guest JD, Yin R, Taherzadeh G, Pierce BG, Barradas-Bautista D, Cao Z, Cavallo L, Oliva R, Sun Y, Zhu S, Shen Y, Park T, Woo H, Yang J, Kwon S, Won J, Seok C, Kiyota Y, Kobayashi S, Harada Y, Takeda-Shitaka M, Kundrotas PJ, Singh A, Vakser IA, Dapkūnas J, Olechnovič K, Venclovas Č, Duan R, Qiu L, Xu X, Zhang S, Zou X, Wodak SJ. Prediction of protein assemblies, the next frontier: The CASP14-CAPRI experiment. Proteins. 2021 Dec;89(12):1800-1823. doi: 10.1002/prot.26222. Epub 2021 Sep 13. PMID: 34453465; PMCID: PMC8616814.
Copy Download .nbib Format: NLM
COVID-19 Social Restrictions: An Opportunity to Re-visit the Concept of Harm Reduction in the Treatment of Alcohol Dependence. A Position Paper.

Frontiers in psychiatry

Kouimtsidis C, Pauly B, Parkes T, Stockwell T, Baldacchino AM.
PMID: 33679480
Front Psychiatry. 2021 Feb 18;12:623649. doi: 10.3389/fpsyt.2021.623649. eCollection 2021.

The COVID-19 pandemic is presenting significant challenges for health and social care systems globally. The implementation of unprecedented public health measures, alongside the augmentation of the treatment capacity for those severely affected by COVID-19, are compromising and limiting the...

Cite
Kouimtsidis C, Pauly B, Parkes T, et al. COVID-19 Social Restrictions: An Opportunity to Re-visit the Concept of Harm Reduction in the Treatment of Alcohol Dependence. A Position Paper. Front Psychiatry. 2021;12:623649doi: 10.3389/fpsyt.2021.623649.
Kouimtsidis, C., Pauly, B., Parkes, T., Stockwell, T., & Baldacchino, A. M. (2021). COVID-19 Social Restrictions: An Opportunity to Re-visit the Concept of Harm Reduction in the Treatment of Alcohol Dependence. A Position Paper. Frontiers in psychiatry, 12623649. https://doi.org/10.3389/fpsyt.2021.623649
Kouimtsidis, Christos, et al. "COVID-19 Social Restrictions: An Opportunity to Re-visit the Concept of Harm Reduction in the Treatment of Alcohol Dependence. A Position Paper." Frontiers in psychiatry vol. 12 (2021): 623649. doi: https://doi.org/10.3389/fpsyt.2021.623649
Kouimtsidis C, Pauly B, Parkes T, Stockwell T, Baldacchino AM. COVID-19 Social Restrictions: An Opportunity to Re-visit the Concept of Harm Reduction in the Treatment of Alcohol Dependence. A Position Paper. Front Psychiatry. 2021 Feb 18;12:623649. doi: 10.3389/fpsyt.2021.623649. eCollection 2021. PMID: 33679480; PMCID: PMC7930817.
Copy Download .nbib Format: NLM
Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles.

bioRxiv : the preprint server for biology

Mu Z, Wiehe K, Saunders KO, Henderson R, Cain DW, Parks R, Martik D, Mansouri K, Edwards RJ, Newman A, Lu X, Xia SM, Bonsignori M, Montefiori D, Han Q, Venkatayogi S, Evangelous T, Wang Y, Rountree W, Tam Y, Barbosa C, Munir Alam S, Williams WB, Pardi N, Weissman D, Haynes BF.
PMID: 34401876
bioRxiv. 2021 Aug 09; doi: 10.1101/2021.08.09.455714.

The success of nucleoside-modified mRNAs in lipid nanoparticles (mRNA-LNP) as COVID-19 vaccines heralded a new era of vaccine development. For HIV-1, multivalent envelope (Env) trimer protein nanoparticles are superior immunogens compared to trimers alone for priming of broadly neutralizing...

Cite
Mu Z, Wiehe K, Saunders KO, et al. Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles. bioRxiv. 2021;doi: 10.1101/2021.08.09.455714.
Mu, Z., Wiehe, K., Saunders, K. O., Henderson, R., Cain, D. W., Parks, R., Martik, D., Mansouri, K., Edwards, R. J., Newman, A., Lu, X., Xia, S. M., Bonsignori, M., Montefiori, D., Han, Q., Venkatayogi, S., Evangelous, T., Wang, Y., Rountree, W., Tam, Y., Barbosa, C., Munir Alam, S., Williams, W. B., Pardi, N., Weissman, D., & Haynes, B. F. (2021). Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.08.09.455714
Mu, Zekun, et al. "Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.08.09.455714
Mu Z, Wiehe K, Saunders KO, Henderson R, Cain DW, Parks R, Martik D, Mansouri K, Edwards RJ, Newman A, Lu X, Xia SM, Bonsignori M, Montefiori D, Han Q, Venkatayogi S, Evangelous T, Wang Y, Rountree W, Tam Y, Barbosa C, Munir Alam S, Williams WB, Pardi N, Weissman D, Haynes BF. Ability of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticles. bioRxiv. 2021 Aug 09; doi: 10.1101/2021.08.09.455714. PMID: 34401876; PMCID: PMC8366792.
Copy Download .nbib Format: NLM
Showing 937 to 947 of 947 entries